Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07740811

Risk Factors and Clinical Implications of Double-J Ureteral Stent Bacterial Colonization: A Prospective Cohort Study

To identify the risk factors associated with bacterial colonization of Double-J ureteral stents and to evaluate its clinical implications, including bacteriuria, UTI, antimicrobial resistance, and stent-related symptoms.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mohamed Fawzy Salman

Cairo, Egypt

Location status: Recruiting

Location contact

Mohamed Fawzy Salman, MD

CONTACT

01111788996

Mohamed Fawzy salman, MD

CONTACT

[email protected]

01111788996

salman, MD

PRINCIPAL_INVESTIGATOR

About this study

Ureteral stents are indispensable in modern urology, but they are frequently complicated by bacterial colonization, biofilm formation, bacteriuria, and infectious morbidity.

Biofilm is clinically important because it promotes microbial persistence on the stent surface, reduces antimicrobial susceptibility, and may contribute to urinary tract infection (UTI) or even severe systemic infection in selected patients.

Prospective studies have shown that febrile ureteral stent-associated UTI occurs in a measurable proportion of patients and can progress to sepsis or septic shock in a subset.

More recent studies also confirm that colonization and resistance patterns vary by patient profile and stent dwell time.A major challenge in this field is that urine culture does not reliably exclude stent colonization.

Several studies have shown that a substantial proportion of patients with sterile urine still have colonized stents, meaning that urine testing alone may underestimate the burden of device-associated infection. In addition, the organisms recovered from stents are often more resistant than those isolated before stent insertion, which raises concern about delayed recognition and suboptimal empiric antibiotic choice in high-risk patients.

These findings support the need to study stent cultures and patient factors together rather than relying on urine culture alone.

The risk factors for bacterial colonization appear to be multifactorial, but the most consistently reported predictor is longer indwelling time. Other factors that have emerged across studies include diabetes mellitus, chronic kidney disease, pregnancy, prior urinary infection, prior catheterization, and albuminuria, although the strength of association is not uniform across all cohorts. Despite this, there is still limited prospective evidence integrating these predictors with clinical outcomes such as febrile UTI, symptom burden, and antimicrobial resistance.

Accordingly, we hypothesize that bacterial colonization of Double-J ureteral stents is associated with identifiable patient- and stent-related risk factors, especially prolonged indwelling time and metabolic or renal comorbidity, and that colonized stents are associated with clinically meaningful outcomes including bacteriuria, resistant organisms, and greater stent-related morbidity.

The significance of this study is that it may help refine patient counseling, improve timing of stent removal, and support targeted surveillance and antibiotic strategies in high-risk patients.

AIM OF THE STUDY To identify the risk factors associated with bacterial colonization of Double-J ureteral stents and to evaluate its clinical implications, including bacteriuria, UTI, antimicrobial resistance, and stent-related symptoms.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing temporary Double-J ureteral stent insertion.
  • Stent inserted for a standard urological indication, including ureteric stone disease, ureteral obstruction, postoperative drainage, or ureteral injury repair.
  • Planned stent removal during the study follow-up period.
  • Availability for clinical follow-up and specimen collection at insertion and removal.
  • Provision of written informed consent.

Exclusion criteria

  • Active urosepsis at the time of stent insertion.
  • Permanent or intended long-term stenting outside the study framework.
  • Concomitant nephrostomy tube or urinary diversion that may confound microbiological results.
  • Known severe immunosuppression or neutropenia if expected to substantially alter colonization risk.
  • Patients with incomplete baseline clinical data.
  • Patients lost to follow-up or whose stent could not be retrieved for microbiological analysis.
  • Refusal to participate.

Treatment and study plan

Urine and stent cultures

Diagnostic Test

All adult patients who undergo Double-J ureteral stent insertion for standard urological indications during the study period will be assessed for eligibility.

Patients will be followed until stent removal, and microbiological evaluation will be performed on both urine and stent specimens at the time of removal

Primary outcomes

  1. Bacterial colonization of the Double-J ureteral stent, defined as positive growth on stent culture at removal.

    Time frame: 2 weeks

    A midstream urine sample will be obtained before stent insertion whenever feasible and again at the time of stent removal.

    At removal, the stent will be handled under sterile conditions and sent for culture. If possible, the proximal and distal stent segments will be cultured separately to assess concordance between device segments.

    Standard microbiological methods will be used to identify organisms and perform antimicrobial susceptibility testing.

    The main endpoint of microbiological assessment will be bacterial colonization of the stent, defined as significant growth from the stent culture regardless of urine culture status.

    patients will be classified as positive (if bacterial growth detected) or negative (if the culture was sterile)

Study contacts

Contact information is provided by the study sponsor or research team.

Mohamed Fawzy Salman, MD

CONTACT

[email protected]

0201111788996

Sponsors and collaborators

Lead sponsor

Al-Azhar University

Other

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 3, 2026
Registry last updated
Aug 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.